Pazopanib as a Second Line Treatment for Uterine and Ovarian Carcinosarcoma: A Single Institutional Study

Journal of Gynecologic Oncology - South Korea
doi 10.3802/jgo.2017.28.e25
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy (KAMJE)

Related search

Second-Line Treatment of Ovarian Cancer

Oncologist
Cancer ResearchMedicineOncology
2000English

Apatinib Monotherapy as a Second-Line Treatment for Patients With Advanced Biliary Tract Cancer: A Retrospective Single-Center Observational Study

2019English

Pazopanib as First Line Treatment for Solitary Fibrous Tumours: The Royal Marsden Hospital Experience

Clinical Sarcoma Research
Oncology
2015English

HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial

Journal of the International Association of Providers of AIDS Care
DermatologyInfectious DiseasesImmunology
2019English

Uterine Carcinosarcoma in a Patient With Didelphys Uterus

Case Reports in Obstetrics and Gynecology
2013English

Metastatic Uterine Carcinosarcoma: A Case Report and Literature Review

Juniper Online Journal of Case Studies
2017English

Safety and Efficacy of 6-Thioguanine as a Second-Line Treatment for Autoimmune Hepatitis

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2018English

Pulmonary Carcinosarcoma Showing an Obvious Response to Pazopanib: A Case Report

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2018English

Molecular Targeted Agents as Second-Line Treatment for Hepatocellular Carcinoma: A Meta-Analysis and Review

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy